Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever

Drug and Alcohol Dependence

Volumn 173, Issue , 2017, Pages 144-150

  Shi, Yuyan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hospitalization; Law; Marijuana; Medical marijuana; Opioid; Overdose

Indexed keywords

MEDICAL CANNABIS; NARCOTIC ANALGESIC AGENT; NARCOTIC AGENT;

ARTICLE; DRUG ABUSE; DRUG OVERDOSE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; OPIATE ADDICTION; PUBLIC POLICY; UNITED STATES; ADULT; CROSS-SECTIONAL STUDY; FEMALE; HEALTH CARE POLICY; LEGISLATION AND JURISPRUDENCE; MALE; MARIJUANA ABUSE; STATISTICS AND NUMERICAL DATA; TRENDS;

ADULT; CROSS-SECTIONAL STUDIES; DRUG OVERDOSE; FEMALE; HEALTH POLICY; HOSPITALIZATION; HUMANS; MALE; MARIJUANA ABUSE; MEDICAL MARIJUANA; NARCOTICS; UNITED STATES;

EID: 85014066290     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2017.01.006     Document Type: Article

References (37)

1. AHRQ, 2016. H-CUPnet. http://hcupnet.ahrq.gov/. Agency for Healthcare Research and Quality.
2. Anderson, D.M., Rees, D.I., Sabia, J.J., Medical marijuana laws and suicides by gender and age. Am. J. Publ. Health 104 (2014), 2369–2376.
3. Angrist, J.D., Pischke, J.S., Mostly Harmless Econometrics: An Empiricist's Companion. 2008, Princeton University Press.
4. Bachhuber, M.A., Saloner, B., Cunningham, C.O., Barry, C.L., Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern. Med. 174 (2014), 1668–1673.
5. Bao, Y., Pan, Y., Taylor, A., Radakrishnan, S., Luo, F., Pincus, H.A., Schackman, B.R., Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff. (Millwood) 35 (2016), 1045–1051.
6. Bradford, A.C., Bradford, W.D., Medical marijuana laws reduce prescription medication use in medicare part D. Health Aff. (Millwood) 35 (2016), 1230–1236.
7. CDC, Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb. Mortal. Wkly. Rep. 60 (2011), 1487–1492.
8. CDC, Wide-Ranging Online Data for Epidemiologic Research (WONDER). 2016, CDC, Atlanta, GA.
9. Christensen, J., Senthilingam, M., Voters in California, Massachusetts and Nevada Approve Recreational Use of Marijuana. 2016, CNN http://www.cnn.com/2016/11/09/health/marijuana-legalization-election-results/index.html.
10. Chu, Y.W., The effects of medical marijuana laws on illegal marijuana use. J. Health Econ. 38 (2014), 43–61.
11. Dowell, D., Zhang, K., Noonan, R.K., Hockenberry, J.M., Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff. (Millwood) 35 (2016), 1876–1883.
12. ElSohly, M.A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., Church, J.C., Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol. Psychiatry 79 (2016), 613–619.
13. Hall, W.D., Lynskey, M., Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev. 24 (2005), 39–48.
14. Hall, W., The adverse health effects of cannabis use: what are they, and what are their implications for policy?. Int. J. Drug Policy 20 (2009), 458–466.
15. Kennedy-Hendricks, A., Richey, M., McGinty, E.E., Stuart, E.A., Barry, C.L., Webster, D.W., Opioid overdose deaths and Florida's crackdown on pill mills. Am. J. Publ. Health 106 (2016), 291–297.
16. Kim, J.H., Santaella-Tenorio, J., Mauro, C., Wrobel, J., Cerda, M., Keyes, K.M., Hasin, D., Martins, S.S., Li, G., State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers. Am. J. Publ. Health 106 (2016), 2032–2037.
17. Kolodny, A., Courtwright, D.T., Hwang, C.S., Kreiner, P., Eadie, J.L., Clark, T.W., Alexander, G.C., The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Ann. Rev. Publ. Health 36 (2015), 559–574.
18. LawAtlas, LawAtlas: The Policy Surveillance Portal. 2016 Accessed on Sep 2016 http://lawatlas.org/.
19. Li, G., Brady, J.E., Lang, B.H., Giglio, J., Wunsch, H., DiMaggio, C., Prescription drug monitoring and drug overdose mortality. Inj. Epidemiol., 1, 2014, 9.
20. Lyapustina, T., Rutkow, L., Chang, H.Y., Daubresse, M., Ramji, A.F., Faul, M., Stuart, E.A., Alexander, G.C., Effect of a pill mill law on opioid prescribing and utilization: the case of Texas. Drug Alcohol Depend. 159 (2016), 190–197.
21. Lynch, M.E., Ware, M.A., Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J. Neuroimmune Pharmacol. 10 (2015), 293–301.
22. Morris, R.G., TenEyck, M., Barnes, J.C., Kovandzic, T.V., The effect of medical marijuana laws on crime: evidence from state panel data, 1990–2006. PLoS One, 9, 2014, e92816.
23. NAMSDL, PDMP Dates of Operation. 2015, The National Alliance for Model State Drug Laws, Charlottesville, VA http://www.namsdl.org/library/580225E9-E469-AFA9-50E7579C1D738E71/.
24. NIDA, DrugFacts—Nationawide Trends. 2015 Accessed on December 2016 https://www.drugabuse.gov/publications/drugfacts/nationwide-trends.
25. Pacula, R.L., Ringel, J., Dobkin, C., Truong, K., The incremental inpatient costs associated with marijuana comorbidity. Drug Alcohol Depend. 92 (2008), 248–257.
26. Pacula, R.L., Hunt, P., Boustead, A., Words can be deceiving: a review of variation among legally effective medical marijuana laws in the United States. J. Drug Policy Anal. 7 (2014), 1–19.
27. Pacula, R.L., Powell, D., Heaton, P., Sevigny, E.L., Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details. J. Policy Anal. Manag. 34 (2014), 7–31.
28. Patrick, S.W., Fry, C.E., Jones, T.F., Buntin, M.B., Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff. (Millwood) 35 (2016), 1324–1332.
29. Paulozzi, L.J., Kilbourne, E.M., Desai, H.A., Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 12 (2011), 747–754.
30. Powell, D., Pacula, R.L., Jacobson, M., Do Medical Marijuana Laws Reduce Addictions and Deaths Related to Pain Killers?. 2015, National Bureau of Economic Research NBER Working Paper No. 21345.
31. Reisfield, G.M., Wasan, A.D., Jamison, R.N., The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Med. 10 (2009), 1434–1441.
32. Room, R., Cannabis Policy: Moving Beyond Stalemate. 2010, Oxford University Press, USA.
33. Sevigny, E.L., Pacula, R.L., Heaton, P., The effects of medical marijuana laws on potency. ‎Int. J. Drug Policy 25 (2014), 308–319.
34. Sidney, S., Beck, J.E., Tekawa, I.S., Quesenberry, C.P., Friedman, G.D., Marijuana use and mortality. Am. J. Publ. Health 87 (1997), 585–590.
35. Sznitman, S.R., Zolotov, Y., Cannabis for therapeutic purposes and public health and safety: a systematic and critical review. Int. J. Drug Policy 26 (2015), 20–29.
36. Warner, M., Hedegaard, H., Chen, L., Trends in Drug-Poisoning Deaths Involving Opioid Analgesics and Heroin: United States. 2014, 1999–2012 Accessed on September 2016 http://www.cdc.gov/nchs/data/hestat/drug_poisoning/drug_poisoning.htm.
37. Wen, H., Hockenberry, J.M., Cummings, J.R., The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances. J. Health Econ. 42 (2015), 64–80.